You, the petitioner


Het jaarverslag over 2016

Het is 1 juli, dus het jaarverslag over het voorgaande jaar moet beschikbaar zijn zegt de wet. Zie voor ons jaarverslag over 2016 en die over voorgaande jaren.

Als donateur, fonds of overheid kunt u zien wat we hebben gedaan met het geld wat binnen kwam. We waarderen vooral de donaties enorm omdat dit toont dat we gewaardeerd worden. Wist u dat u uw donatie ook als aftrekpost kunt opvoeren? Lees hierover of over alle betaalmiddelen die we ondersteunen op doneerpagina.


Brief aan de voorzitter van de Vaste Kamercommissie Volksgezondheid, Welzijn en Sport.

Parliament of the Kingdom of the Netherlands House of Representatives Committee for Health, Welfare and Sports

For the attention of: Mrs Helma Lodders, Committee chair

4th March 2019

Dear Mrs Lodders,

Tobacco Harm Reduction and the Dutch National Prevention Agreement: Letter from 36 International Experts and Academics in Tobacco Control.

We are a group of nicotine, tobacco and addiction researchers, health professionals, and tobacco control policy experts in support of tobacco harm reduction as part of comprehensive tobacco control. We respectfully write to you in view of the upcoming debate in the Dutch Lower House about the National Prevention Agreement (1) - a topic which has generated significant interest among researchers, health professionals and experts working in tobacco control policy in Europe and across the globe.

We very much welcome the objectives and existing tobacco control measures set out in the Agreement which are in line with the WHO Framework Convention on Tobacco Control.

+

Any policy intervention that reduces smoking in the Netherlands has our full support. We regret however, that the Agreement fails to acknowledge the important role that products that do not involve combustion and inhalation of smoke can play in reducing the harms caused by smoking. Such products include forms of low nitrosamine smokeless tobacco such as snus, vaping technologies and pharmaceutical or pure nicotine products. From a health perspective, the major distinction between nicotine products is whether they are combustible or non-combustible. It is well known that it is the smoke, not the nicotine, which causes almost all of the smoking related diseases and non-combustible products have a clear role to play in reducing smoking prevalence to meet the ambitious objectives set out in the Agreement.

The public health opportunities for harm reduction are vast, and in the case of vaping (e-cigarettes) these have been well described by the Royal College of Physicians of London (RCP) in its thorough April 2016 report (2) and more recently by McNeil el al. (2018) in a report to Public Health England (3). For example, on the subject of relative risk, based on smoke and vapour toxicology the RCP stated:

"Although it is not possible to precisely quantify the long-term health risks associated with e-cigarettes, the available data suggest that they are unlikely to exceed 5% of those associated with smoked tobacco products, and may well be substantially lower than this figure". (5.5)

On the subject of smoking cessation, there is increasing evidence from Randomised Controlled Trials (RCT) that have been designed specifically to explore effects on tobacco smoking, that vaping products (e-cigarettes) can help smokers to stop smoking. A Cochrane review published in 2016 concluded that smokers using an e-cigarette were more likely to quit compared to those using a placebo at 6 months (4). More recently, a RCT of e-cigarettes versus Nicotine Replacement Therapy (NRT) alongside behavioural support in England, reported an almost two-fold increase in 12 month quit rates with e-cigarettes (5).

On the question of what the products are being used for, the RCP is clear they are alternatives to smoking and used primarily by smokers to reduce their health risks.

“…the available evidence to date indicates that e-cigarettes are being used almost exclusively as safer alternatives to smoked tobacco, by confirmed smokers who are trying to reduce harm to themselves or others from smoking, or to quit smoking completely. “

Similarly, in a recent review of findings from five large-scale surveys of 60,000 young people in the United Kingdom (6) although some experimentation was reported, regular use remained very low, ranging from 0.1 to 0.5%. Recent survey data from the UK suggests this pattern has not changed7. The report conclude that:

“…surveys across the UK show a consistent pattern: most e-cigarette experimentation does not turn into regular use, and levels of regular use in young people who have never smoked remain very low.”

As is the case across the globe, in the Netherlands there are many smokers that are unable or unwilling to quit, not least of all, the poorest and most disadvantaged in society who find smoking cessation the most difficult. This large group, including those suffering from mental illness, would benefit from switching to smoke-free products. In this regard it is critical that adult smokers can be informed about these innovative products and receive non-misleading information about their relative risk.

However subjecting e-cigarettes and other smoke-free products to the same restrictions as for combustible cigarettes can have unintended consequences and can favour the tobacco industry. For example, treating vaping the same as smoking in public places has no scientific basis but could discourage smokers from using a less risky product, causing harm to health by perpetuating smoking and rewarding the cigarette trade. Advertising display bans for e-cigarettes similarly favour the incumbent product (cigarettes) and form a barrier to the much less risky innovative new products. The RCP recognises the potential for unintended consequences and states that:

“However, if [a risk-averse, precautionary] approach also makes e-cigarettes less easily accessible, less palatable or acceptable, more expensive, less consumer friendly or pharmacologically less effective, or inhibits innovation and development of new and improved products, then it causes harm by perpetuating smoking.” (Section 12.10 page 187)

Whilst we welcome tighter restrictions on cigarette smoking, treating non-combustible products such as e-cigarettes in the same way, sends the wrong message that smoke-free products are as harmful as cigarettes. This will discourage smokers from switching, which leads to the unintended consequence that cigarette use is prolonged. Obviously this goes against the Agreement’s objective to eradicate smoking.

We respectfully request that the Lower House carefully assess the role that non-combustible products such as e-cigarettes can play in reducing tobacco smoking and recommend an exemption for e-cigarettes from the bans on display/advertisement and smoking in public places. We are more than willing to provide you with further information and our perspective on the international developments in the field of tobacco harm reduction and draw your attention to recent letter to the World Health Organisation (WHO) from 72 specialists in the field (8) which offers some guiding principles for consideration for the Framework Convention on Tobacco Control (FCTC). We would welcome the opportunity to contribute to a round-table in your Committee should you decide to organize such type of event.

We confirm that signatories report no conflicts with respect to FCTC Article 5.3 and no financial conflicts of interest with respect to tobacco or e-cigarette companies under the International Committee of Medical Journal Editors (UCJME) reporting standard.

Yours sincerely,

David B Abrams PhD. Professor Dept of Social and Behavioral Sciences NYU College of Global Public Health New York University. United States

Frank Baeyens,PhD Professor Faculty of Psychology and Educational Sciences KU Leuven Belgium

Clive Bates, MA, MSc Director, Counterfactual Consulting Former Director, Action on Smoking and Health UK London United Kingdom

Linda Bauld, BA PhD FHEA FRCPE Bruce and John Usher Chair in Public Health Usher Institute University of Edinburgh Deputy Director, UK Centre for Tobacco & Alcohol Studies Honorary Professor, University of Stirling United Kingdom

Ron Borland PhD, FASSA Nigel Gray Distinguished Fellow in Cancer Prevention, The Cancer Council Victoria, Melbourne Vic 3004

Thomas H. Brandon, Ph.D. Department Chair and Program Leader, Health Outcomes and Behavior Moffitt Distinguished Scholar Director, Tobacco Research & Intervention Program Moffitt Cancer Center Professor, University of South Florida Departments of Psychology and Oncologic Sciences

Pasquale Caponnetto Professor of Clinical and General Psychology Center of Excellence for the acceleration of HArm Reduction – CoEHAR University of Catania via S. Sofia 78, Catania, Italy

Sharon Cox, PhD Research Fellow Centre for Addictive Behaviours Research School of Applied Sciences London South Bank University United Kingdom

Lynne Dawkins, PhD
Associate Professor Centre for Addictive Behaviours Research
School of Applied Sciences London South Bank University
United Kingdom

Jean-François Etter, PhD Professor of Public Health Institute of Global Health Faculty of Medicine University of Geneva

Konstantinos Farsalinos, MD, MPH Researcher Onassis Cardiac Surgery Center National School of Public Health University of Patras, Greece

Stuart Ferguson Associate Professor Division of Medicine, School of Medicine
College of Health and Medicine University of Tasmania Private Bag 34 Hobart 7001 Tasmania

William T. Godshall, MPH Executive Director Smokefree Pennsylvania 1926 Monongahela Avenue Pittsburgh, PA 15218 412-351-5880 United States

Peter Hajek, PhD Professor of Clinical Psychology Director, Tobacco Dependence Research Unit Wolfson Institute of Preventive Medicine, Queen Mary University of London United Kingdom

Jacques Le Houezec, PhD Independent consultant in Public Health & Tobacco dependence - Smoking Cessation Specialist Rennes, France. Honorary Clinical Associate Professor, UK Centre for Tobacco and Alcohol Studies, School of Medicine, University of Nottingham, UK.

Jason Hughes, PhD Professor and Head of School of Media, Communication and Sociology University of Leicester Leicester, LE1 7LA United Kingdom

Sarah Jackson, PhD CPsychol Senior Research Associate UCL Tobacco and Alcohol Research Group Department of Behavioural Science and Health University College London United Kingdom

Martin J Jarvis, DSc OBE Emeritus Professor of Health Psychology Department of Behavioural Science & Health University College London United Kingdom

Leon Kosmider, PhD, PharmD Research Assistant Professor Technical Director, Bioanalytical Shared Resource Laboratory School of Pharmacy Department of Pharmaceutics Virginia Commonwealth University Richmond United States

Lynn T. Kozlowski, PhD Professor of Community Health and Health Behavior Former Dean School of Public Health and Health Professions University at Buffalo, State University of New York New York United States

Christopher E. Lalonde, PhD
Professor of Psychology University of Victoria British Columbia Canada

Karl E Lund, PhD Senior Researcher Norwegian Institute of Public Health Oslo, Norway

Colin Paul Mendelsohn, MB BS (Hons) Conjoint Associate Professor School of Public Health and Community Medicine University of New South Wales Sydney Australia

Bernhard-Michael Mayer, PhD Professor of Pharmacology and Toxicology Institute of Pharmaceutical Sciences Karl-Franzens-Universität Graz Austria

Fares Mili, MD, CTTS Addictologyst & Pulmonologyst Chairman Tunisian Society of Tobacology and Addictive Behaviours (STTACA) Tunisia

Caitlin Notley, PhD Senior Lecturer in Mental Health Addictions Research Group Norwich Medical School University of East Anglia Norwich United Kingdom

Konstantinos Poulas, PhD Associate Professor
Department of Pharmacy University of Patras Head of the Institute NoSmoke.Team Patras Science Park Greece

Lars M. Ramström, PhD Principal Investigator Institute for Tobacco Studies Täby, Sweden

Louise Ross Clinical Consultant National Centre for Smoking Cessation Training
Dorchester United Kingdom

Lion Shahab, PhD Associate Professor Department of Behavioural Science and Health University College London United Kingdom

Andrzej Sobczak, PhD Head of Department of General and Inorganic Chemistry Medical University of Silesia Sosnoiwec, Jagiellonska 4, Poland

Roberto A Sussman, PhD Department of Gravitation and Field Theories Institute for Nuclear Research, National Autonomous University of Mexico, ICN-UNAM Representing Pro-Vapeo Mexico AC Mexico

David Sweanor, JD Chair of Advisory Board of the Center for Health Law, Policy and Ethics University of Ottawa Canada

Umberto Tirelli MD Professor Director, Cancer Center Clinica Mede Sacile Italy

Robert West, PhD Professor of Health Psychology and Director of Tobacco Studies Department of Behavioural Science and Health University College London United Kingdom

Alex Wodak AM, Emeritus Consultant, Alcohol and Drug Service, St Vincent's Hospital President, Australian Drug Law Reform Foundation Director, Australia21 Darlinghurst, NSW, 2010, Australia


  1. National Prevention Agreement:

  2. Royal College of Physicians (London), Nicotine without smoke: tobacco harm reduction. 28 April 2016

  3. McNeil, A., Brose, LS., Calder, R., Bauld, L. & Robson, D. (2018). Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by Public Health England.

  4. Hartmann-Boyce, J., McRobbie, H., Bullen, C., Begh, R., Stead, L.F. & Hajek, P. (2016). Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews, Issue 9, Art. No.: CD010216.

  5. Hajek, P., Phillips, A., Przulj, D., Pesola, F., Myers Smith, K., Bisal, N., Li, J., Parrott, S., Sasieni, P., Dawkins, L., Ross, L., Goniewicz, M., Wu, Q. & McRobbie, H. (2019). A randomized trial of e-cigarettes versus nicotine-replacement therapy. New England Journal of Medicine, Jan 30. DOI: 10.1056/NEJMoal808779.

  6. Bauld, L ., MacKintosh, AM., Eastwood, B., Ford, A., Moore, G., Dockrell, M., Arnott, D., Cheeseman, H. & McNeill, A. (2017). Young people’s use of e-cigarettes across the United Kingdom: findings from five surveys 2015-2017. International Journal of Environmental Research and Public Health, 14 (9), 973.

  7. McNeil, A., Brose, LS., Calder, R., Bauld, L. & Robson, D. (2019). Vaping In England: an evidence update February 2019. A report commissioned by Public Health England. London: Public Health England.

  8. Letter from seventy-two specialists in nicotine science, policy and practice.


Op 26 augustus 2019 heeft de petitie de 4.600 grens doorbroken. Dank allemaal voor de steun voor de strijd tegen de verstening van de Parkhaven!.

2019-08-26 | Petition Geen woonwijk rondom Euromastpark

Van de FNV pagina, waarom de actie op 2 september hard nodig is.


"Waarom is staken en actievoeren nodig? De vraag naar jeugdzorg wordt steeds groter. Je bent veel werktijd kwijt aan administratie.

+

Je hebt te weinig tijd, budget en middelen voor je cliënten. Je kunt je niet verder ontwikkelen en er is geen ruimte voor innovatie. Het werk in de jeugdzorg wordt steeds onaantrekkelijker en daardoor komt er ook geen nieuw personeel meer bij. Je werkdruk is alsmaar hoger geworden. Niet zo vreemd dus, dat je het werk in de jeugdzorg niet meer aankunt of ander werk gaat zoeken. En dat wil je eigenlijk helemaal niet, want je hebt het mooiste beroep op aarde.

Zo kunnen we niet verder Zelfs Jeugdzorg Nederland geeft aan dat het zo echt niet verder kan gaan. De zorg staat zo onder druk dat de kwaliteit van de hulp niet meer vanzelfsprekend is. De situatie is voor medewerkers én cliënten niet meer verantwoord.

Eenmalig extra geld voor jeugdzorg is niet genoeg De jeugdzorg krijgt in 2019 eenmalig € 420 miljoen van de minister. En in 2020 en 2021 komt er ook eenmalig € 300 miljoen bij. Maar dat is niet genoeg. Er is veel meer geld nodig om de tekorten aan te vullen en om het werk voor jou weer aantrekkelijk te maken.

Wat is er wel nodig voor goede jeugdzorg? De tekorten in de jeugdzorg moeten worden aangevuld. Daarvoor is € 750 miljoen nodig. Met dit bedrag is er nog geen geld voor extra's. Je kunt er de sector alleen mee stabiliseren.

Er is ook € 200 miljoen nodig voor jou en je collega's. Bijvoorbeeld om de werkdruk te kunnen verlagen, voor scholing, de balans tussen werk en privé, gezond ouder worden en meer. Maar voor jou geeft het ministerie van VWS geen geld. Het geld wat de overheid nu geeft is maar voor 3 jaar. Maar wij willen een doorlopende investering in de jeugdzorg. De kostprijs moet ieder jaar betaald worden en dan moet er nog geld over zijn voor vernieuwing en ontwikkeling. Het nu beschikbare geld van gemeenten is niet geoormerkt. Dat betekent dat er geen vast budget is voor jeugdzorg. Dat gemeente kan het geld ook voor iets anders kan gebruiken. Bijvoorbeeld het openhouden van de bibliotheek of het zwembad."

2019-08-26 | Petition Onze jeugd is meer waard

Voor Nederland is het belangrijk dat er nu een echte verandering komt. Te veel mensen leven in armoede in een tijd van economische groei.

Over armoede en dakloos zijn, intussen meer dan 30.000 mensen in Nederland en stijgende hebben wij het volgende artikel gepubliceerd; Zelfs de middeninkomens geven aan moeite te hebben met rondkomen.

+

Hoe moet dat dan zijn voor minima? Wat is er aan de hand met het gevoel voor onze medemensen? Hoe komt het dat onze democratische samenleving dit laat gebeuren en wij de mensenrechten schenden?

Graag ondertekenen en delen

Wij hebben als actie-comité geen vertrouwen meer in het bestuur van V&VN! Jullie ook niet? Dan graag onderstaande petitie ondertekenen en zoveel mogelijk delen op social media!

760.000 euro subsidie?

Volgens een raadslid gaat er 760.000 euro subsidie van de Gemeente Rotterdam naar dit commerciële paardenevenement. ( het prijzengeld is al hoger).

+

Wereldwijd gaan er honderden miljarden om in de paardensport. En wie betaald eigenlijk voor het herstel van de grasvelden en het bos?

Voorbeelden meegenomen naar kamerleden en pers!

hoi allemaal, Ik heb jullie onlangs gevraagd om voorbeelden te geven waaruit blijkt dat je nu al veel problemen ondervindt op de werkvloer! Ik heb echt heel veel voorbeelden gehad waarvoor dank! Met name de problemen in de wijk en bij de reizigersverpleegkundigen zijn heel groot! Heb afgelopen dinsdag met dhr. Kerstens van de PvdA gesproken samen met het actie-comité en aan hem heb ik duidelijk kunnen maken dat al jullie problemen NU spelen en dat daar ook NU wat aan moet gebeuren! Maandag j.l.

+

heb ik gesproken met een journalist van het NRC, ook aan haar heb ik voorbeelden van jullie kunnen vertellen! Vandaag ook weer heb ik interview met journalist van de Volkskrant gehad, en ook weer de problemen verteld. Komende weken vinden wederom gesprekken plaats en neem nogmaals de problemen mee! We blijven strijden en hopen dat de wet echt definitief niet doorgaat, maar ook met spoed de problemen nu al opgelost gaan worden! Blijf vooral voorbeelden sturen! Hartelijke groet, Rini

Lid van Milieudefensie? Lees onderstaand bericht!

Hoi, Ben je lid van Milieudefensie? Klil dan op onderstaande link. Ze wiolen een extra Ledenvergadering houden over 5G.

+

Hiervoor zijn min. 250 stemmen nodig.

Doe mee! Zo kunnen we het getij keren!

Alfred Melse

2019-08-22 | Petition Stop 5G